Last reviewed · How we verify

NCT03578653: MY-OT for PD

Merging Yoga and Occupational Therapy for Parkinson Disease: Phase 2

Completed NA Last updated 25 July 2019
What this trial tests

NA trial testing Merging Yoga and Occupational Therapy for Parkinson disease in Parkinson Disease in 18 participants. Completed in 31 March 2019.

Timeline
1 June 2018
Primary endpoint
31 December 2018
31 March 2019

Quick facts

Lead sponsorColorado State University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment18
Start date1 June 2018
Primary completion31 December 2018
Estimated completion31 March 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Colorado State University

Who can join

18 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The full program is focused on identifying and reducing risk factors surrounding falls. Based on previous research, we believe that occupational therapy group classes and adaptive yoga are an ideal pairing to reduce fall risk. The occupational therapy sessions will consist of lecture, group discussion, and activities designed to target biological, behavioral, environmental, and socioeconomic factors that contribute to fall risk specifically for people with Parkinson's disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other Colorado State University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03578653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing